ANKE BIO(300009)2024-04-25 09:54Financial Performance - The company's operating revenue for Q1 2024 was ¥656,092,096.17, representing a year-on-year increase of 10.42% compared to ¥594,174,209.84 in the same period last year[13]. - Net profit attributable to shareholders of the listed company reached ¥217,749,931.36, up 17.31% from ¥185,618,139.71 in the previous year[13]. - The net profit after deducting non-recurring gains and losses was ¥204,934,342.97, reflecting a 15.03% increase from ¥178,156,883.51 year-on-year[13]. - Basic and diluted earnings per share were both ¥0.1299, an increase of 17.13% from ¥0.1109 in the previous year[13]. - The company's total comprehensive income for the first quarter of 2024 was ¥221,942,342.95, compared to ¥188,850,882.44 in the same period last year, reflecting a growth of 17.5%[47]. - Net profit for Q1 2024 reached ¥221,942,342.95, representing a growth of 17.5% from ¥188,850,882.44 in Q1 2023[28]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,126,705,641.39, a 3.55% increase from ¥4,950,760,486.04 at the end of the previous year[13]. - The total liabilities amount to 5,126,705,641.39, up from 4,950,760,486.04, indicating an increase of about 3.1%[25]. - The total current assets amount to 2,512,247,494.21, an increase from 2,325,483,458.75 in the previous period, reflecting a growth of approximately 8.1%[25]. - Non-current assets total 2,614,458,147.18, slightly decreasing from 2,625,277,027.29 in the previous period[25]. - The company's long-term equity investments decreased from 167,344,181.81 to 128,450,676.95, a decline of approximately 23.2%[25]. - The total non-current liabilities were ¥167,764,792.30, slightly down from ¥171,347,690.88 in the previous year[26]. Cash Flow - The net cash flow from operating activities decreased by 28.36%, amounting to ¥154,730,370.05 compared to ¥215,982,444.58 in the same period last year[13]. - Cash inflow from operating activities totaled 558,257,243.14 in the prior period[51]. - Cash outflow from investing activities was 920,356,399.38 in the previous period[49]. - The net cash flow from investing activities was -173,330,460.50 in the prior period[49]. - The net increase in cash and cash equivalents was 49,030,829.21 in the previous period, indicating a growth of 13.4%[49]. Shareholder Information - Shareholders' equity attributable to the listed company reached ¥3,966,402,036.48, up 6.13% from ¥3,737,399,547.01 at the end of the previous year[13]. - The major shareholders include Song Lihua with a 26.50% stake and Song Liming with a 6.85% stake, indicating concentrated ownership[18]. - The total number of restricted shares at the end of the period is 461,139,070 shares, with 0 shares released during the current period[22]. Research and Development - The company is actively promoting production line construction and advancing research projects to support steady growth in performance[15]. - Research and development expenses for Q1 2024 were ¥37,176,848.42, a rise of 5.1% compared to ¥35,377,092.33 in Q1 2023[27]. - The company has initiated clinical trials for its self-developed oncolytic virus cancer drug, which received approval from the National Medical Products Administration on April 12, 2024[41]. Investment Activities - The company reported a significant increase in investment activities, with net cash flow from investing activities showing a decrease of 44.19% due to substantial purchases of bank financial products[17]. - The company reported a financial income of ¥1,511,862.47, down from ¥1,619,883.04 in the previous year[27]. - The company reported a significant increase in investment income, which rose by 202.32% to ¥1,303,243.94 from ¥431,079.56, primarily due to higher returns from bank financial products[44]. - The fair value changes in financial assets resulted in a gain of ¥3,497,728.11, a 520.15% increase from ¥564,009.72, driven by substantial changes in the value of bank financial products held[44].